Molecular Imaging Agents in Development for IO Treatment Response

Webinar

Molecular Imaging Agents in Development for IO Treatment Response

Imaging biomarkers play an increasingly important role in the assessment and prediction of immuno-oncology treatment responses. The recent emergence of PET radioligands, which facilitate visualization of molecular markers of immune cell activation, provides an attractive alternative to tissue biopsy when evaluating tumor immunologic status and treatment efficacy. Non-invasive imaging also enables the investigation of multiple lesions simultaneously and longitudinally, empowering new opportunities to identify and address heterogeneous lesion responses.

Join Sean Carlin, PhD as he:

Reviews the novel immuno-oncology PET imaging agents moving towards clinical use
Describes how these agents are being employed
Discusses novel imaging metrics which may be used to annotate treatment efficacy

Access On-Demand Below

Full Name(Required)

Business Email(Required)

Phone Number

Institute or Company(Required)

Service Line Interest(Required)

Therapeutic Area(Required)

I would like to subscribe to Perceptive marketing communications. By subscribing, you consent to receive emails from Perceptive. We respect your privacy, and you can manage your communication preferences anytime. You can find the Perceptive privacy policy.

Phone

This field is for validation purposes and should be left unchanged.

Molecular Imaging Agents in Development for IO Treatment Response

Webinar

Molecular Imaging Agents in Development for IO Treatment Response

Access On-Demand Below

Stay Updated